Regeneron Pharmaceuticals' Net Cash Flow rose 2783.01% to $610.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $634.4 million, marking a year-over-year increase of 35570.33%. This contributed to the annual value of $634.4 million for FY2025, which is 35570.33% up from last year.
As of Q4 2025, Regeneron Pharmaceuticals' Net Cash Flow stood at $610.9 million, which was up 2783.01% from $497.9 million recorded in Q3 2025.
In the past 5 years, Regeneron Pharmaceuticals' Net Cash Flow ranged from a high of $1.4 billion in Q3 2021 and a low of -$2.0 billion during Q2 2023
For the 5-year period, Regeneron Pharmaceuticals' Net Cash Flow averaged around $45.9 million, with its median value being $153.4 million (2022).
Its Net Cash Flow has fluctuated over the past 5 years, first tumbled by 410546.56% in 2023, then surged by 57325.49% in 2025.
Quarter analysis of 5 years shows Regeneron Pharmaceuticals' Net Cash Flow stood at -$546.8 million in 2021, then grew by 29.52% to -$385.4 million in 2022, then soared by 249.82% to $577.4 million in 2023, then decreased by 17.23% to $477.9 million in 2024, then grew by 27.83% to $610.9 million in 2025.
Its Net Cash Flow was $610.9 million in Q4 2025, compared to $497.9 million in Q3 2025 and -$1.1 billion in Q2 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value